Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31714043 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL2029800 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL5526027 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL2034753 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL5490059 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL2034755 | 1.00 | ALDH1A1 (0.76) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL16084531 | 0.93 | KDM4E (0.84) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL1683870 | 0.86 | ALDH1A1 (0.58) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL9249925 | 0.86 | ALDH1A1 (1.00) | ALDH1A1MAPTHSD17B10KDM4EPOLB | |
| SCHEMBL3825265 | 0.86 | ALDH1A1 (1.00) | ALDH1A1MAPTHSD17B10KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045401-B2 | Methods for treating or ameliorating a melanoma and killing melanoma cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-06-02 | — | — | US | disclosed |
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2099778-A2 | AMIDO ANTI-VIRAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080181866-A1 | Amido Anti-viral Compounds | GENELABS TECHNOLOGIES, INC. | 2008-07-31 | — | — | US | disclosed |
| WO-2008064218-A2 | AMIDO ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266675-A1 | LIPOPROTEINS, LIPOPEPTIDES AND ANALOGS, AND METHODS FOR MAKING AND USING THEM | LIPG, VEGFA, LIPE | ALDH1A1 4419/4885MAPT 3939/4885HSD17B10 1842/4885 |
| US-20080181866-A1 | Amido Anti-viral Compounds | ZC3HAV1, U2SURP, ZC3HAV1L | ALDH1A1 4630/4885MAPT 52/4885HSD17B10 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.